BIO-NIVESH (Science & Technology)
BIO-NIVESH (Science & Technology)
Why In News:
BIO-NIVESH, was recently launched by the Department of Biotechnology (DBT), an investor–innovator platform aimed at connecting biotech startups with investors and facilitating access to capital.
About BIO-NIVESH
Organised by:BIRAC (Biotechnology Industry Research Assistance Council), the implementation arm of DBT for strengthening India’s biotechnology innovation ecosystem.
Nature: It is a recurring investor–innovator platform, not a separate fund or government scheme.
Inaugural edition: Connected 20 biotech and deep-tech startups with around 50 investors, under the theme “Ideas, Investment, Impact”.
Core objective: To facilitate the transition of biotech innovations from laboratory research to commercialisation by improving access to private investment.
Funding gap: It seeks to address the biotech “Valley of Death”-the gap between early-stage scientific innovation and the availability of capital required for large-scale development and commercial production.
Biotech Ecosystem
RDI Fund: BIRAC also serves as the Second-Level Fund Manager for the ₹1 lakh crore Research Development and Innovation (RDI) Fund, linking biotechnology financing with the wider national innovation ecosystem.
BioE3 Policy: The Biotechnology for Economy, Environment and Employment (BioE3) Policy provides a broader policy framework for promoting biotechnology-led economic growth, environmental sustainability and employment.
National Biopharma Mission: It supports biopharmaceutical research, innovation and manufacturing, particularly by strengthening collaboration between academia and industry.
India’s Bioeconomy
India’s bioeconomy has grown nearly 20-fold- from about $10 billion in 2014 to $165.7 billion in 2024, reaching $195.3 billion in 2025 (roughly ₹16 lakh crore), per the India Bioeconomy Report (IBER) 2026.
The government’s target under the BioE3 Policy is $300 billion (~₹25 lakh crore) by 2030.
India now has over 11,800 registered biotech startups (11,855 per IBER 2026), up from fewer than 100 a decade ago.
India remains the third-largest biotechnology destination in the Asia-Pacific region.